The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.

Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.

Data showing that endpoints were met for both signs and symptoms of dry eye disease should position Kala’s KRI-121 for US approval. The company hopes to differentiate with short-term flare treatment.

The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.